Stryker (NYSE:SYK), a global leader in medical technologies, announced the addition of two new products to its Foot & Ankle portfolio – the Osteotomy Truss System™ (OTS) and Ankle Truss System™ (ATS), recently acquired from 4WEB Medical. The company will feature both the OTS and ATS, the newly acquired Artelon portfolio, and other products at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting taking place in Vancouver, Canada from Sept. 11-14, 2024.

The new Ankle Truss System (ATS), which includes Arthrosphere^® and Arthrocube™ implants, is an innovative product designed to restore limb length while providing structural integrity for the limb during tibiotalocalcaneal (TTC) fusions. The ATS implants feature Truss Implant Technology™, offering an open architecture designed to provide structural support and promote fusion. It is cleared for use with Stryker’s T2 Ankle Arthrodesis Nail or Valor Hindfoot Fusion Nail and will be readily available in three different shapes to enable expedited scheduling of surgeries for patients requiring immediate ankle fusion. The Osteotomy Truss System (OTS) is comprised of Cotton, Evans, and Utility wedges, which offers a comprehensive solution for all of a surgeon's osteotomy needs. It is indicated for internal bone fixation and osteotomies in the foot and ankle and is currently available for use. The ATS will debut at the AOFAS annual meeting and will be available in the coming months.

“The addition of the ATS and the integration of Artelon reflects our commitment to providing surgeons with enhanced orthopaedic solutions to achieve the best possible patient outcomes,” said Michael Rankin, vice president of marketing and medical education of Stryker’s Foot & Ankle business. “We will never stop our dedication to advancing our offerings to meet the evolving needs of our customers for all foot and ankle procedures. We look forward to showcasing our expanded portfolio at the AOFAS conference.”

Stryker will also be highlighting several other solutions at AOFAS, booth #601, including for the first time the Artelon Flexband, which is a next-generation biomaterial designed to help restore natural strength and elasticity to healing soft tissues. Stryker will also be celebrating 10 years of excellence of the Infinity Total Ankle System, which is a market leader in low-profile implants, demonstrating 98.8% survivorship at two years¹ and 95.9% survivorship at seven years.² It provides reliable, anatomically contoured components for maintaining joint function and patient mobility in total ankle replacement.

About Stryker

Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.

A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.

The information presented is intended to demonstrate the breadth of Stryker’s product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker’s products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of products in your area.

Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Ankle Truss System, Artelon, Flexband, Infinity, Osteotomy Truss System, Stryker, T2, Valor. All other trademarks are trademarks of their respective owners or holders.

References:

1. Townshend D, Bing A, Blundell C, Clough T, Davenport J, Davies H, Davis J, Dhar S, Hepple S, Kakwani R, Karski M, Makwana N, McKinley J, Murty A, Raglan M, Shalaby H, Sharpe I, Smith R, Taylor H, Goldberg A. Two to Five-Year Outcomes of Total Ankle Arthroplasty with the Infinity Fixed-Bearing Implant: A Concise Follow-up of a Previous Report. J Bone Joint Surg Am. 2023 Dec 6;105(23):1846-1856. doi: 10.2106/JBJS.22.01294. Epub 2023 Oct 16. PMID: 38063779; PMCID: PMC10695343.
2. Based on 7-year revision rate from the 20th Annual Report of the UK National Joint Registry for INFINITY (Table 3.A4)

Copyright © 2024 Stryker
Content ID: AP-017648

View source version on businesswire.com: https://www.businesswire.com/news/home/20240911818131/en/